NEWSROOM
News
Announcements, media coverage and milestones from De Motu Cordis.
De Motu Cordis (DMC) announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination product
De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites.
Forbes magazine features DMC founder – how Professor John Fraser aims to ensure that through innovation, patients thrive, not just survive
Professor John Fraser’s Belfast born grandmother was one of the first women to qualify in Northern Ireland as a doctor. It was the 1900s, and she was there to rebel, to change outcomes and to prove that women could do just as well as men.
DMC Director, Doctor Glen Richards, a 2023 UQ Alumni Award winner!
Dr Glen Richards is a business leader, entrepreneur and veterinarian.
De Motu Cordis (DMC) welcomed Queensland Treasurer and Minister for Trade and Investment Honourable Cameron Dick MP
On April 4, 2023, De Motu Cordis (DMC) welcomed Queensland Treasurer and Minister for Trade and Investment Honourable Cameron Dick MP to our Brisbane premises.
Press Release 27 February 2023
De Motu Cordis reports progress on the development of its dry powder inhaler (DPI) containing epinephrine (adrenaline) for inhaled anaphylaxis treatment.
JPM Week – San Francisco
In the first global sharing of its innovative solution for anaphylaxis treatment, De Motu Cordis (DMC) reports progress on its dry powder inhaler (DPI) containing epinephrine (adrenaline) for inhaled anaphylaxis treatment.
